• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SenesTech Announces 2025 Financial Results Driven by Strong Growth in E-Commerce

    3/12/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials
    Get the next $SNES alert in real time by email

    SURPRISE, Ariz., March 12, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, today announced financial results for the fourth quarter and the full year ended December 31, 2025.

    SenesTech, Inc. is a pioneer in fertility control solutions for managing rodent populations. (PRNewsfoto/SenesTech, Inc.)

    2025 Highlights

    • Revenue increased by 20% to $2.2 million in 2025 as compared to 2024, driven by strong growth in the Company's overall e-commerce channels despite the impact associated with the Company's transition to directly managing Amazon sales of Evolve® Rat and Evolve Mouse. Excluding this transition-related impact, we estimate revenue would have increased by approximately 30%. As the transition becomes fully integrated, direct Amazon management is expected to meaningfully enhance both revenue and operating margins in the future.
    • Gross profit margin was 62.5% in 2025, compared to 54.1% in 2024, driven by the higher margin profile of the Evolve product line and manufacturing improvements.
    • Net loss for 2025 was $6.4 million compared to $6.2 million in 2024. 2025 included $631,000 in one-time legal expenses and $135,000 in non-cash operating lease expense. Excluding these items, Adjusted Net Loss would have been $5.6 million.
    • Adjusted EBITDA loss improved to $5.3 million in 2025, compared to $5.8 million in 2024, reflecting continued revenue growth and improved gross margins partially offset by higher operating investments.
    • The balance sheet was strengthened by capital raises completed in 2025, resulting in cash and short-term investments of $8.6 million at the end of 2025. The Company believes this capital will be sufficient to provide operating runway through approximately the second quarter of 2027.

    Operational and Strategic Highlights

    • E-commerce Growth: E-commerce revenue increased 88% year-over-year from 2024 to 2025, driven by strong growth on Amazon and the Company's direct-to-consumer website, notwithstanding the loss of an estimated $200,000 in 2025 revenue as a result of the Company's transition to directly managing Amazon sales. If the Company had recognized an additional $200,000 in E-Commerce revenue for this transition, E-Commerce revenue growth would have been 130%.
    • Amazon Direct Management: SenesTech has begun directly managing Amazon sales of Evolve Rat and Evolve Mouse, transitioning from third-party management to strengthen product presentation and customer communications, leverage performance data to optimize marketing, and retain a greater portion of e-commerce economics. While the transition created an approximately $200,000 fourth quarter revenue impact, management expects direct control to drive higher revenue and stronger margins once fully integrated.
    • Field Validation: Multi-month Evolve deployments in two urban study areas delivered measurable reductions in rodent activity within five months, including a 79% decline in rat activity at one site and more than a 50% decline at a second site.
    • International Expansion: Evolve secured regulatory approval in New Zealand (with the initial stocking order shipped to exclusive partner Evicom) and expanded international footprint in Belize by adding the Belize Raptor Center as an official distributor.
    • CEO Transition: SenesTech's Board has initiated a formal search for a new CEO following Joel Fruendt's retirement, and appointed Dr. Jamie Bechtel to the newly created role of Interim Executive Chair to support leadership continuity and strategic execution during the transition period.

    Commentary

    "2025 marked meaningful progress, with continued field validation, revenue growth, improved margins, and a stronger balance sheet," said Joel Fruendt, President and CEO of SenesTech. "We believe field validation of efficacy becomes a powerful catalyst for expanded acceptance in the market, as reflected in the strong growth of our e-commerce channel, which is now more than 50% of our annual revenue. We are leaning further into the direct-to-consumer and e-commerce opportunities, strengthening our control of the customer experience, improving performance management, and enhancing our ability to capture more value as adoption expands."

    "With a CEO transition plan underway, the Board remains focused on continuity, alignment, and disciplined execution as we support management in scaling the business," said Dr. Jamie Bechtel, Interim Executive Chair of SenesTech. "With a growing body of validation and a sharpened go-to-market approach, we are focused on executing with discipline, expanding adoption, and building long-term stockholder value."

    Use of Non-GAAP Financial Measure

    Adjusted EBITDA and Adjusted Net Loss are non-GAAP measures. However, these measures are not intended to be a substitute for those financial measures reported in accordance with GAAP. These have been included because management believes that, when considered together with the GAAP figures, they provide meaningful information related to our operating performance and liquidity and can enhance an overall understanding of financial results and trends. We use these non-GAAP financial measures as part of our overall assessment of our performance, including the preparation of our annual operating budget and quarterly forecasts, to evaluate the effectiveness of our business strategies, and to communicate with our board of directors concerning our financial performance. These adjustments may be calculated by us differently than other companies that disclose measures with the same or similar term. See our attached financials for a reconciliation of the non-GAAP measures to the nearest GAAP measure.

    Conference Call Details

    Date and Time: Thursday, March 12, 2026, at 5:00 pm ET

    Live Webcast Information: Interested parties can access the conference call via a live Internet webcast, which is available in the Investor Relations section of the Company's website at https://app.webinar.net/g3BpDpdDZ14 or https://senestech.investorroom.com/. 

    Replay: A webcast replay will be available in the Investor Relations section of the Company's website at https://senestech.investorroom.com/ for 90 days.

    About SenesTech

    SenesTech is committed to creating healthier environments by managing animal pest populations through birth control. The company's groundbreaking products, including Evolve rodent birth control, integrate seamlessly into pest management programs, significantly enhancing their effectiveness while reducing reliance on traditional poisons. SenesTech's mission is to create cleaner cities, more efficient businesses, and healthier communities with products that are effective and sustainable.

    For more information visit https://senestech.com/. 

    Safe Harbor Statement

    This press release contains "forward-looking statements" within the meaning of federal securities laws, and we intend that such forward-looking statements be subject to the safe harbor created thereby. Such forward-looking statements include, among others, statements regarding the effectiveness and benefits of our products; the potential of direct management of Amazon sales of Evolve products to meaningfully enhance both revenue and operating margins; the Company's expected operating runway; the potential of field validation of efficacy to expand acceptance in the market; the Company's plans to lean further into direct-to-consumer and e-commerce opportunities and potential benefits thereof; CEO transition matters; and the impact of Adjusted EBITDA and Adjusted Net Loss metrics.

    Forward-looking statements may describe future expectations, plans, results, or strategies and are often, but not always, made through the use of words such as "believe," "may," "future," "plan," "will," "should," "expect," "anticipate," "eventually," "project," "estimate," "continuing," "intend" and similar words or phrases. You are cautioned that such statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those reflected by such forward-looking statements. Such factors include, among others, the successful commercialization of our products; market acceptance of our products; our financial performance, including our ability to fund operations; regulatory approval and regulation of our products; challenges transitioning to direct management of Amazon sales of Evolve products or the results of such direct management not being as expected; having to use cash at times and in ways other than as planned; and other factors and risks identified from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2025. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

    CONTACT:  

    Investor Relations: Robert Blum, Lytham Partners, LLC, 602-889-9700, [email protected]

    Company: Tom Chesterman, Chief Financial Officer, SenesTech, Inc., 928-779-4143

    SENESTECH, INC.

    BALANCE SHEETS

    (In thousands, except share and per share data)

    (Unaudited)





    As of December 31,



    2025



    2024

    ASSETS







    Current assets:







    Cash and cash equivalents

    $         7,575



    $         1,307

    Short-term investments

    994



    —

    Accounts receivable, net

    201



    335

    Inventory

    994



    794

    Prepaid expenses and other current assets

    297



    377

    Total current assets

    10,061



    2,813

    Right to use assets, operating leases

    2,336



    —

    Property and equipment, net

    410



    407

    Other noncurrent assets

    36



    58

    Total assets

    $       12,843



    $         3,278









    LIABILITIES AND STOCKHOLDERS' EQUITY







    Current liabilities:







    Accounts payable

    $           183



    $           215

    Accrued expenses

    383



    278

    Current portion of operating lease liability

    139



    —

    Current portion of notes payable

    61



    56

    Deferred revenue

    32



    12

    Total current liabilities

    798



    561

    Operating lease liability, less current portion

    2,332



    -

    Notes payable, less current portion

    145



    206

    Total liabilities

    3,275



    767

    Stockholders' equity:







    Common stock

    5



    1

    Additional paid-in capital

    152,043



    138,607

    Accumulated deficit

    (142,480)



    (136,097)

    Total stockholders' equity

    9,568



    2,511

    Total liabilities and stockholders' equity

    $       12,843



    $         3,278

     

    SENESTECH, INC.

    STATEMENTS OF OPERATIONS

    (In thousands, except share and per share data)

    (Unaudited)





    Three Months Ended

    December 31,



    Years Ended

    December 31,



    2025



    2024



    2025



    2024

    Revenues, net

    $           421



    $           501



    $         2,221



    $         1,857

    Cost of sales

    188



    196



    833



    853

    Gross profit

    233



    305



    1,388



    1,004

    Operating expenses:















    Research and development

    453



    424



    1,698



    1,712

    Selling, general and administrative

    1,661



    1,138



    6,195



    5,541

    Total operating expenses

    2,114



    1,562



    7,893



    7,253

    Loss from operations

    (1,881)



    (1,257)



    (6,505)



    (6,249)

    Other income (expense):















    Interest income

    82



    8



    144



    56

    Interest expense

    (5)



    (7)



    (22)



    (22)

    Miscellaneous income

    —



    1



    —



    31

    Other income, net

    77



    2



    122



    65

    Net loss

    $        (1,804)



    $        (1,255)



    $        (6,383)



    $        (6,184)

    Weighted average shares outstanding — basic and diluted

    5,223,015



    1,029,592



    3,275,983



    697,974

    Loss per share — basic and diluted

    $         (0.35)



    $         (1.22)



    $         (1.95)



    $         (8.86)

     

    SenesTech Inc.

    Itemized Reconciliation Between Net Loss and Adjusted EBITDA (non-GAAP)

    (In thousands)

    (Unaudited)





    Three Months Ended

    December 31,



    Years Ended

    December 31,



    2025



    2024



    2025



    2024

    Net loss (as reported, GAAP)

    $        (1,804)



    $        (1,255)



    $        (6,383)



    $        (6,184)

    Non-GAAP adjustments:















    Interest income, net

    (77)



    (1)



    (122)



    (34)

    Stock-based compensation expense

    36



    80



    264



    326

    Depreciation expense

    32



    41



    135



    156

    Non-cash operating lease expense (benefit)

    48



    (5)



    135



    (8)

    One-time legal costs

    275



    —



    631



    —

    Severance costs

    -



    -



    27



    13

    Gain on sale of assets

    -



    -



    —



    (28)

    Total non-GAAP adjustments

    314



    115



    1,070



    425

    Adjusted EBITDA loss (non-GAAP)

    $        (1,490)



    $        (1,140)



    $        (5,313)



    $        (5,759)

     

    SenesTech Inc.

    Reconciliation of Net Loss and Adjusted Net Loss (non-GAAP)

    (In thousands)

    (Unaudited)





    Years Ended

    December 31,



    Percent Change



    2025



    2024



    Net loss (as reported, GAAP)

    $        (6,383)



    $        (6,184)



    3 %

    Non-GAAP adjustments:











    One-time legal costs

    631



    —





    Non-cash operating lease expense (benefit)

    135



    (8)





    Adjusted net loss (non-GAAP)

    $        (5,617)



    $        (6,192)



    (9) %

     

     

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/senestech-announces-2025-financial-results-driven-by-strong-growth-in-e-commerce-302712612.html

    SOURCE SenesTech, Inc.

    Get the next $SNES alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNES

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SNES
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $200,635 worth of shares (85,901 units at $2.34) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/19/26 7:57:41 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $56,667 worth of shares (31,346 units at $1.81) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/13/26 5:20:17 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $15,480 worth of shares (8,569 units at $1.81) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/6/26 5:40:20 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $SNES
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SenesTech Announces 2025 Financial Results Driven by Strong Growth in E-Commerce

    SURPRISE, Ariz., March 12, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, today announced financial results for the fourth quarter and the full year ended December 31, 2025. 2025 HighlightsRevenue increased by 20% to $2.2 million in 2025 as compared to 2024, driven by strong growth in the Company's overall e-commerce channels despite the impact associated with the Company's transition to directly managing Amazon sales of Evolve® Rat and Evolve Mouse. Excluding this transition-related impact, we estimate re

    3/12/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech to Report Fourth Quarter and Fiscal Year 2025 Financial Results on Thursday, March 12, 2026

    Financial results to be released after market close; Conference call to be conducted at 5:00 p.m. Eastern timePHOENIX, March 9, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, will report financial results for its fourth quarter and fiscal year 2025, ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Company has scheduled a conference call that same day, Thursday, March 12, 2026, at 5:00 pm ET, to review the results. Fourth Quarter and Fiscal Year 2024 Conference Call DetailsDa

    3/9/26 4:15:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech Reports Significant Reductions in Rodent Activity Following Evolve® Deployments in Urban Field Studies

    SURPRISE, Ariz., Feb. 18, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES) ("SenesTech" or the "Company"), a leader in birth control solutions for managing rodent populations, today reported significant reductions in rodent activity following multi-month deployments of Evolve® Rat Birth Control in two urban locations. Results were measured using standardized tracking plate data conducted over a five-month period. Location A – Deployment Initiated April 2025In the first monitored area, where Evolve placement began in April 2025, tracking plate data collected from August 2025 th

    2/18/26 8:00:00 AM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $SNES
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $200,635 worth of shares (85,901 units at $2.34) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/19/26 7:57:41 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $56,667 worth of shares (31,346 units at $1.81) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/13/26 5:20:17 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $15,480 worth of shares (8,569 units at $1.81) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/6/26 5:40:20 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $SNES
    SEC Filings

    View All

    SenesTech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - SenesTech, Inc. (0001680378) (Filer)

    3/12/26 4:06:15 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Amendment: SEC Form SCHEDULE 13G/A filed by SenesTech Inc.

    SCHEDULE 13G/A - SenesTech, Inc. (0001680378) (Subject)

    2/2/26 5:26:13 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Amendment: SenesTech Inc. filed SEC Form 8-K: Leadership Update

    8-K/A - SenesTech, Inc. (0001680378) (Filer)

    1/28/26 5:26:33 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $SNES
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:28:08 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:12:23 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SEC Form SC 13G filed by SenesTech Inc.

    SC 13G - SenesTech, Inc. (0001680378) (Subject)

    11/12/24 4:30:48 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $SNES
    Financials

    Live finance-specific insights

    View All

    SenesTech Announces 2025 Financial Results Driven by Strong Growth in E-Commerce

    SURPRISE, Ariz., March 12, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, today announced financial results for the fourth quarter and the full year ended December 31, 2025. 2025 HighlightsRevenue increased by 20% to $2.2 million in 2025 as compared to 2024, driven by strong growth in the Company's overall e-commerce channels despite the impact associated with the Company's transition to directly managing Amazon sales of Evolve® Rat and Evolve Mouse. Excluding this transition-related impact, we estimate re

    3/12/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech to Report Fourth Quarter and Fiscal Year 2025 Financial Results on Thursday, March 12, 2026

    Financial results to be released after market close; Conference call to be conducted at 5:00 p.m. Eastern timePHOENIX, March 9, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, will report financial results for its fourth quarter and fiscal year 2025, ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Company has scheduled a conference call that same day, Thursday, March 12, 2026, at 5:00 pm ET, to review the results. Fourth Quarter and Fiscal Year 2024 Conference Call DetailsDa

    3/9/26 4:15:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech Reports Third Quarter 2025 Financial Results with Record Revenue and Adjusted EBITDA

    77% Revenue Growth in Evolve® Rodent Birth Control™ Products Strong Cash Balance and Progress Toward Profitability SURPRISE, Ariz., Nov. 10, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), the leader in fertility control for managing animal pest populations and the only manufacturer of EPA-compliant Rodent Birth Control™ products today announced its financial results for the third quarter ended September 30, 2025. Q3 2025 Financial Highlights Revenues increased by 43% to $690,000, a record for the Company, from $482,000 in Q3 2024.Evolve® Rodent Birth Control product sales

    11/10/25 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $SNES
    Leadership Updates

    Live Leadership Updates

    View All

    SenesTech Announces CEO Transition Plan

    Board To Initiate Search For New Leadership As Current CEO Plans Retirement Dr. Jamie Bechtel Named Interim Executive Chair To Further Support Transition PHOENIX, Jan. 28, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a pioneer in fertility control solutions for managing rodent populations, today announced that Joel Fruendt, President and Chief Executive Officer, has informed the Board of Directors of his intent to retire. The Board will commence a formal search for a successor. Mr. Fruendt will continue to serve as President and CEO until the search is completed or until June 30, 2026, whichever occurs first.

    1/28/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech Names Nicole Williams as Chief Revenue Officer

    PHOENIX, Feb. 16, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", ))), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today reported the appointment of Nicole Williams as Chief Revenue Officer. Ms. Williams was previously Chief Strategy Officer, and this appointment is part of an expansion and restructuring of the sales organization and commercialization efforts. The restructuring of the team comes after yet another quarter and fiscal ye

    2/16/23 9:00:00 AM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech Announces Appointment of Vector and Pest Control Industry Veteran Joel Fruendt as Chief Executive Officer

    PHOENIX, Nov. 14, 2022 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES, ", SenesTech", or the ", Company", ))), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today announced the appointment of Joel Fruendt as SenesTech's new Chief Executive Officer, succeeding Ken Siegel. Mr. Siegel, who is expected to retire at the end of the year, will remain as an Executive Director, in a consultative role, through the transition period. This leadership transition is part of SenesTech's ongoing strategic plan to drive the commercialization of ContraPest, its flagship product.

    11/14/22 9:10:00 AM ET
    $SNES
    Agricultural Chemicals
    Industrials